Neuro-oncology advances · 2026
Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score-matched analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Shuo-Fu, Lee Yi-Yen, Liu Chun-Yu, Lin Chun-Fu, Hsu Sanford P C, Chang Feng-Chi, Wu Chih-Chun, Lin Shih-Chieh, Lin Ko-Han, Lee Jia-Cheng, Peir Jinn-Jer, Chou Fong-In, Tanaka Hiroki, Liu Yu-Ming, Chen Yi-Wei
Аннотация
BACKGROUND: Boron neutron capture therapy (BNCT) presents a targeted re-irradiation strategy for recurrent glioblastoma. However, its survival benefit remains unclear, as few studies have compared the addition of BNCT to bevacizumab (BEV) with BEV alone or other salvage approaches.
METHODS: We retrospectively analyzed 171 adults with recurrent glioblastoma: 116 treated with BEV ± chemotherapy (control group) and 55 treated with BNCT plus BEV ± chemotherapy (BNCT group). To improve comparability, propensity score matching was performed using age, performance status, recurrent tumor volume, recurrence-to-salvage-treatment interval, the number of relapses, re-resection, and chemotherapy use. Survival outcomes were assessed using Kaplan-Meier estimates and Cox proportional hazards models.
RESULTS: In the matched cohort (n = 98), progression-free survival (PFS) was significantly longer in the BNCT group compared with the control group (median 5.34 vs 3.70 months, hazard ratio [HR]: 0.54, P = .026), whereas overall survival (OS) was comparable (HR: 0.86, P = .524). The objective response rate was significantly higher in the BNCT group compared with the control group (67.4% vs 47.0%; P = .041). Multivariable analysis showed that the absence of callosal involvement (odds ratio [OR]: 0.10, P = .033) and higher minimum absorbed dose (OR: 1.09; P = .028) were independently associated with better BNCT response.
CONCLUSIONS: Boron neutron capture therapy plus BEV was associated with higher objective response rate and improved PFS compared with BEV alone in patients with recurrent glioblastoma, although no OS difference was demonstrated. These findings support BNCT as a salvage strategy but warrant prospective validation.
METHODS: We retrospectively analyzed 171 adults with recurrent glioblastoma: 116 treated with BEV ± chemotherapy (control group) and 55 treated with BNCT plus BEV ± chemotherapy (BNCT group). To improve comparability, propensity score matching was performed using age, performance status, recurrent tumor volume, recurrence-to-salvage-treatment interval, the number of relapses, re-resection, and chemotherapy use. Survival outcomes were assessed using Kaplan-Meier estimates and Cox proportional hazards models.
RESULTS: In the matched cohort (n = 98), progression-free survival (PFS) was significantly longer in the BNCT group compared with the control group (median 5.34 vs 3.70 months, hazard ratio [HR]: 0.54, P = .026), whereas overall survival (OS) was comparable (HR: 0.86, P = .524). The objective response rate was significantly higher in the BNCT group compared with the control group (67.4% vs 47.0%; P = .041). Multivariable analysis showed that the absence of callosal involvement (odds ratio [OR]: 0.10, P = .033) and higher minimum absorbed dose (OR: 1.09; P = .028) were independently associated with better BNCT response.
CONCLUSIONS: Boron neutron capture therapy plus BEV was associated with higher objective response rate and improved PFS compared with BEV alone in patients with recurrent glioblastoma, although no OS difference was demonstrated. These findings support BNCT as a salvage strategy but warrant prospective validation.